Brokerage firm Jefferies Maintains its rating on Bristol-Myers Squibb Co(NYSE:BMY). In a research note issued to the investors, the brokerage major Raises the price-target to $80.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Jul 14, 2016.
In a different note, On Jun 14, 2016, Jefferies said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Raises the price-target to $76.00 per share. The shares have been rated ‘Hold’ by the firm. On May 9, 2016, Credit Suisse said it Maintains its rating on Bristol-Myers Squibb Co. In the research note, the firm Raises the price-target to $75.00 per share. The shares have been rated ‘Outperform’ by the firm.
Bristol-Myers Squibb Co (BMY) shares turned negative on Mondays trading session with the shares closing down -0.04 points or -0.05% at a volume of 37,94,127. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $76.36. The peak price level was also seen at $76.36 while the days lowest was $75.62. Finally the shares closed at $75.96. The 52-week high of the shares is $77.12 while the 52-week low is $51.82. According to the latest information available, the market cap of the company is $126,801 M.
Bristol-Myers Squibb Co(BMY) last announced its earnings results on Apr 28, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $4.39B. Analysts had an estimated revenue of $4.21B. Earnings per share were $0.74. Analysts had estimated an EPS of $0.64.
Several Insider Transactions has been reported to the SEC. On Jul 11, 2016, Lamberto Andreotti (director) sold 23,200 shares at $74.65 per share price.Also, On Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at $72.69 per share price.On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at $70.79 per share price, according to the Form-4 filing with the securities and exchange commission.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.